Patients who develop psychosis or agitated behavior secondary to
neurological disorders present a therapeutic dilemma. The authors review
clinical efficacy and side effect profiles of clozapine in a cohort of 16
patients with various neurobehavioral disorders. One-third showed a marked
decrease in symptoms while on clozapine. However, one- quarter developed an
acute confusional state; of these, all had diffuse slowing on their
baseline EEG prior to starting the drug.